REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

SillaJen Inc. (South Korea)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: SillaJen Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

SillaJen Inc. operates as a privately-held biotechnology company engaged in engineering and developing oncolytic virus immunotherapeutics. The company owns and develops Pexa-Vec (JX-594), JX929 vaccinia virus strain, and pipeline development products which may help cure cancer. SillaJen Inc. is based in Busan, with an office in Seoul, South Korea. The company was incorporated in 2006.

Headquarters
6F 252 Geumjeong-Ro, Geumjeong-Gu
Busan; Busan;

Contact Details: Purchase the SillaJen Inc. report to view the information.

Website: http://www.sillajen.com

Basic Information
Total Employees:
Purchase the SillaJen Inc. report to view the information.
Outstanding Shares:
Purchase the SillaJen Inc. report to view the information.
Registered Capital:
Purchase the SillaJen Inc. report to view the information.
Financial Auditors:
Purchase the SillaJen Inc. report to view the information.
Incorporation Date:
March 28, 2006
Key Executives
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Auditor
Ownership Details
Purchase this report to view the information.
5.2%
Purchase this report to view the information.
2.4%
Purchase this report to view the information.
1.1%
Subsidiaries
Sillajen Biotherapeutics Inc
Sillajen Usa Inc
Company Performance
Financial values in the chart are available after SillaJen Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-62.05%▼
Total operating revenue
-68.28%▼
Operating profit (EBIT)
-32.8%▼
EBITDA
-44.69%▼
Net Profit (Loss) for the Period
-40.54%▼
Total assets
-27.55%▼
Total equity
-30.52%▼
Operating Profit Margin (ROS)
-1175.8%▼
Net Profit Margin
-1222.94%▼
Return on Equity (ROE)
-4.91%▼
Debt to Equity Ratio
-1.39%▼
Quick Ratio
0.14%▲
Cash Ratio
0.96%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo